目的 观察盐酸坦洛新缓释片联合前列康片治疗Ⅲ型前列腺炎的临床疗效。方法 选取2014年11月-2015年5月河池市人民医院泌尿外科收治的Ⅲ型前列腺炎患者85例,按照随机数字表法随机分为对照组(42例)和治疗组(43例)。对照组患者口服前列康片,3片/次,3次/d。治疗组患者在对照组基础上给予盐酸坦洛新缓释片,饭后口服,1片/d。两组患者均连续用药6周。观察两组患者临床疗效,并比较治疗前后NIS-CPSI评分、前列腺液中白细胞计数、pH值。结果 治疗后,对照组、治疗组的总有效率分别为66.67%、86.05%,两组总有效率比较差异具有统计学意义(P<0.05)。治疗后,两组患者疼痛、排尿症状、生活质量和NIH-CPSI评分均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组这些指标的下降程度优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者前列腺液中白细胞计数、pH值均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组这些指标的下降幅度优于对照组,两组比较差异具有统计学意义(P<0.05)。结论 盐酸坦洛新缓释片联合前列康片治疗Ⅲ型前列腺炎具有较好的临床疗效,能够显著降低NIH-CPSI评分,安全性好,值得在临床上进一步推广和应用。

Objective To explore the clinical effects of Tamsulosin hydrochloride Sustained Release Tablets combined with Qianliekang Tablets in treatment of typeⅢ prostatitis.Methods Patients (85 cases) with type Ⅲ prostatitis in Department of Urology Surgery of The People's Hospital of Hechi from November 2014 to May 2015 were divided into control (42 cases) and treatment (43 cases) groups according to the random number table method. The patients in the control group were po administered with Qianliekang Tablets, 3 tablets/time, three times daily. The patients in the treatment group were poadministered with Tamsulosin hydrochloride Sustained Release Tablets on the basis of control group, 1 tablet/time, once daily. The patients in two groups were treated for 6 weeks. After treatment, the efficacies were evaluated, and NIS-CPSI scores, white blood cell and pH value of prostatic fluid in two groups before and after treatment were compared.Results After treatment, the efficacies in the control and treatment groups were 66.67% and 86.05%, respectively, and there were differences between two groups (P < 0.05). After treatment, pain, urinary symptoms, quality of life and NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, white blood cell counts and pH values of prostatic fluid in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05).Conclusion Tamsulosin hydrochloride Sustained Release Tablets combined with Qianliekang Tablets has clinical curative effect in treatment of typeⅢ prostatitis, can significantly reduce NIH-CPSI scores, higher security, which has a certain clinical application value.